{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:00:33Z","timestamp":1791896433326,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T00:00:00Z","timestamp":1546473600000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Takara Bio"},{"name":"Novartis Pharmaceuticals"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.ymthe.2017.10.012","type":"journal-article","created":{"date-parts":[[2017,10,20]],"date-time":"2017-10-20T06:45:18Z","timestamp":1508481918000},"page":"269-279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":128,"title":["Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients"],"prefix":"10.1016","volume":"26","author":[{"given":"Katherine T.","family":"Marcucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie K.","family":"Jadlowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ting","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Suhoski-Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa E.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Kulikovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minnal","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon F.","family":"Lacey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Plesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Joseph","family":"Melenhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce L.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl H.","family":"June","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2017.10.012_bib1","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T\u00a0cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2017.10.012_bib2","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2002-09-2800","article-title":"Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial","volume":"101","author":"Muul","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.10.012_bib3","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T\u00a0cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2017.10.012_bib4","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1182\/blood-2012-07-447250","article-title":"Antiviral effects of autologous CD4 T\u00a0cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV","volume":"121","author":"Tebas","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.10.012_bib5","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJM199008303230904","article-title":"Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction","volume":"323","author":"Rosenberg","year":"1990","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2017.10.012_bib6","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/mt.2014.3","article-title":"Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in\u00a0vivo","volume":"22","author":"Cesana","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.10.012_bib7","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","article-title":"A third-generation lentivirus vector with a conditional packaging system","volume":"72","author":"Dull","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2017.10.012_bib8","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1404588","article-title":"A modified \u03b3-retrovirus vector for X-linked severe combined immunodeficiency","volume":"371","author":"Hacein-Bey-Abina","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2017.10.012_bib9","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1084\/jem.176.4.1125","article-title":"Helper virus induced T\u00a0cell lymphoma in nonhuman primates after retroviral mediated gene transfer","volume":"176","author":"Donahue","year":"1992","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2017.10.012_bib10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1089\/10430340150218440","article-title":"Supplemental guidance on testing for replication-competent retrovirus in retroviral vector-based gene therapy products and during follow-up of patients in clinical trials using retroviral vectors","volume":"12","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2017.10.012_bib11","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/mt.2010.278","article-title":"Replication-competent lentivirus analysis of clinical grade vector products","volume":"19","author":"Cornetta","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.10.012_bib12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-1-59745-409-4_17","article-title":"Detection of replication competent retrovirus and lentivirus","volume":"506","author":"Sastry","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2017.10.012_bib13","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/mt.2011.288","article-title":"Replication-competent retroviruses in gene-modified T\u00a0cells used in clinical trials: is it time to revise the testing requirements?","volume":"20","author":"Bear","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.10.012_bib14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/jgm.2691","article-title":"Patient monitoring and follow-up in lentiviral clinical trials","volume":"15","author":"McGarrity","year":"2013","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.ymthe.2017.10.012_bib15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJM200301163480314","article-title":"A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency","volume":"348","author":"Hacein-Bey-Abina","year":"2003","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2017.10.012_bib16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T\u00a0cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2017.10.012_bib17","doi-asserted-by":"crossref","first-page":"227ra33","DOI":"10.1126\/scitranslmed.3007280","article-title":"Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity","volume":"6","author":"Braun","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2017.10.012_bib18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nm1393","article-title":"Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1","volume":"12","author":"Ott","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2017.10.012_bib19","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nm.2088","article-title":"Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease","volume":"16","author":"Stein","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2017.10.012_bib20","unstructured":"Food and Drug Administration. (2006). Guidance for industry: gene therapy clinical trials \u2013 observing subjects for delayed adverse events. Guidance from the Center for\u00a0Biologics Evaluation and Research. https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/CellularandGeneTherapy\/ucm078719.pdf."},{"key":"10.1016\/j.ymthe.2017.10.012_bib21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In\u00a0vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2017.10.012_bib22","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nbt0997-871","article-title":"Multiply attenuated lentiviral vector achieves efficient gene delivery in\u00a0vivo","volume":"15","author":"Zufferey","year":"1997","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2017.10.012_bib23","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/mt.2008.5","article-title":"Physiological promoters reduce the genotoxic risk of integrating gene vectors","volume":"16","author":"Zychlinski","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.10.012_bib24","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T\u00a0cells and increased antileukemic efficacy in\u00a0vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.10.012_bib25","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1182\/blood.V74.2.876.876","article-title":"Expression of human adenosine deaminase from various strong promoters after gene transfer into human hematopoietic cell lines","volume":"74","author":"Hock","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.10.012_bib26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1089\/104303404772680029","article-title":"Evaluation of plasmid DNA removal from lentiviral vectors by benzonase treatment","volume":"15","author":"Sastry","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2017.10.012_bib27","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1525-0016(03)00167-9","article-title":"Development of a sensitive assay for detection of replication-competent recombinant lentivirus in large-scale HIV-based vector preparations","volume":"8","author":"Escarpe","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.10.012_bib28","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/hum.1994.5.5-567","article-title":"Characterization of a replication-competent retrovirus resulting from recombination of packaging and vector sequences","volume":"5","author":"Otto","year":"1994","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2017.10.012_bib29","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40291-016-0229-9","article-title":"Long-Term Safety Follow-Up of Subjects Previously Treated with Non-Replicating Retroviral Vector-Based Gene Therapies","volume":"20","author":"Mohanlal","year":"2016","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.ymthe.2017.10.012_bib30","doi-asserted-by":"crossref","first-page":"132ra153","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T\u00a0cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2017.10.012_bib31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","article-title":"Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer","volume":"5","author":"Hege","year":"2017","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2017.10.012_bib32","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJM199206253262605","article-title":"Risk of leukemia after chemotherapy and radiation treatment for breast cancer","volume":"326","author":"Curtis","year":"1992","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2017.10.012_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199001043220101","article-title":"Leukemia following chemotherapy for ovarian cancer","volume":"322","author":"Kaldor","year":"1990","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2017.10.012_bib34","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJM199902043400504","article-title":"Risk of leukemia after platinum-based chemotherapy for ovarian cancer","volume":"340","author":"Travis","year":"1999","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2017.10.012_bib35","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nm0502-423","article-title":"Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement","volume":"8","author":"Aiuti","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2017.10.012_bib36","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/mt.2009.16","article-title":"Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T\u00a0cells","volume":"17","author":"Wang","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.10.012_bib37","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood-2007-12-128751","article-title":"Resistance of mature T\u00a0cells to oncogene transformation","volume":"112","author":"Newrzela","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.10.012_bib38","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature09328","article-title":"Transfusion independence and HMGA2 activation after gene therapy of human \u03b2-thalassaemia","volume":"467","author":"Cavazzana-Calvo","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2017.10.012_bib39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1089\/humc.2013.119","article-title":"The committee for advanced therapies\u2019 of the European Medicines Agency reflection paper on management of clinical risks deriving from insertional mutagenesis","volume":"24","author":"Aiuti","year":"2013","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.ymthe.2017.10.012_bib40","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.V96.3.785","article-title":"Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T\u00a0cells in human immunodeficiency virus-infected subjects","volume":"96","author":"Mitsuyasu","year":"2000","journal-title":"Blood"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001617305282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001617305282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T05:22:15Z","timestamp":1603171335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001617305282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S1525001617305282"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2017.10.012","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2017.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}